Foundayo
orforglipron — GLP-1 receptor agonist (oral small-molecule) by Eli Lilly and Company
Foundayo is a prescription GLP-1 receptor agonist containing the active ingredient orforglipron, manufactured by Eli Lilly and Company and FDA-approved on April 1, 2026. It is administered as an oral tablet once daily, and produced approximately 12.4% body-weight loss in the ATTAIN-1 trial over 72 weeks.
Key Facts
- Active ingredient: orforglipron
- Drug class: GLP-1 receptor agonist (oral small-molecule)
- Manufacturer: Eli Lilly and Company
- FDA approval: 2026-04-01 (NDA 220934)
- Route & frequency: oral, once daily
- Maximum dose: 36 mg once daily
- Mean weight loss (ATTAIN-1): 12.4% over 72 weeks
- Primary indication: Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
FDA-Approved Indications
- Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
Dosing
| Route | oral |
| Frequency | Once daily |
| Starting Dose | 3 mg once daily |
| Maintenance | 12 mg or 36 mg once daily |
| Max Dose | 36 mg once daily |
| Titration | 3 mg x 4 weeks, then 6 mg x 4 weeks, then 12 mg. May escalate to 24 mg and then 36 mg at 4-week intervals based on tolerability. |
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | 21-27% | 2/5 |
| Diarrhea | 15-20% | 2/5 |
| Vomiting | 10-16% | 3/5 |
| Constipation | 8-14% | 1/5 |
| Indigestion/dyspepsia | 6-10% | 2/5 |
| Abdominal pain | 5-9% | 2/5 |
| Headache | 5-8% | 1/5 |
| Fatigue | 4-7% | 1/5 |
| Hair loss | 3-5% | 2/5 |
| Pancreatitis (rare) | <0.5% | 5/5 |
Cost
| List Price | Pricing announced at U.S. launch (April 2026); confirm with LillyDirect |
| With Insurance | Formulary coverage evolving; many commercial plans expected to require prior authorization |
| Savings Card | Eli Lilly savings program details emerging via LillyDirect |
Pricing last updated 2026-04-16. Actual costs vary by pharmacy, insurance plan, and location.
Compare Foundayo With
Boxed Warning
Risk of thyroid C-cell tumors. In rodents, GLP-1 receptor agonists cause thyroid C-cell tumors. It is unknown whether orforglipron causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
Sources & References
FDA & Regulatory
Clinical Trial Records
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.